Modified red blood cells
CN122396764APending Publication Date: 2026-07-14WESTLAKE THERAPEUTICS (SHANGHAI) CO LTD +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- WESTLAKE THERAPEUTICS (SHANGHAI) CO LTD
- Filing Date
- 2024-12-12
- Publication Date
- 2026-07-14
AI Technical Summary
Technical Problem
The existing drug delivery systems have problems with poor stability, unwanted toxicity and immune response in terms of in vivo use, and the red blood cell modification methods have problems with cell membrane destruction and non-covalent junctions and easy dissociation.
Method used
Covalent linkage of the red blood cell to the effector active agent is achieved by coupling the linker polypeptide enzyme (AEP) such as OaAEP1.
Benefits of technology
A more reliable, stable, convenient and low-cost method for red blood cells as a drug delivery platform is realized, improving the activity, in vivo half-life, distribution and safety of the drug.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000041_0000 
Figure 00000041_0001 
Figure 00000042_0000
Abstract
A method of modifying red blood cells by an OaAEP1 enzyme mediated ligation reaction, coupling red blood cells via a linker to an effector active agent, such as an antibody. Also provided are such modified red blood cells, and uses thereof, for example, for effector active agents, such as antibodies.
Need to check novelty before this filing date? Find Prior Art